Phase III Study of KW-2246 (A Double Blind Study of KW-2246 Compared to Placebo for Breakthrough Pain Episodes in Cancer Patients)
Phase of Trial: Phase III
Latest Information Update: 10 Mar 2017
At a glance
- Drugs Fentanyl (Primary)
- Indications Acute pain; Cancer pain
- Focus Registrational; Therapeutic Use
- Sponsors Kyowa Hakko Kirin
- 12 Dec 2013 Manufacturing and marketing approval of Abstral in Japan was received on 20 September 2013, ahead of expectations, and the launch has commenced, according to an Orexo media release.
- 11 Dec 2013 Abstral was launched in Japan, according to a Kyowa Hakko Kirin media release.
- 24 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.